Interaction Checker

Interações de Roflumilaste

Roflumilaste (Daliresp), inibidor da PDE4, tem 108 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 53; moderadas: 54; leves: 1; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações graves (53)

  • AclidínioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • AminofilinametilxantinaGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Aprepitantoinibidor da CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Arformoterolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Armodafinilaestimulante do SNCGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Bosentanaindutor da CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Budesonida + formoterolcorticosteroideGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • CarbamazepinaanticonvulsivanteGrave

    Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (bula de Roflumilaste, Interações medicamentosas)

  • CenobamatoanticonvulsivanteGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • ClobazambenzodiazepínicoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Deferasiroxsuplemento de ferroGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • DexametasonacorticosteroideGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • EfavirenzantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Efavirenz + lamivudina + tenofovirantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Epinefrina (adrenalina)simpaticomiméticoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • EslicarbazepinaanticonvulsivanteGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • EtravirinaantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • FenitoínaanticonvulsivanteGrave

    Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (bula de Roflumilaste, Interações medicamentosas)

  • FenobarbitalbarbitúricoGrave

    Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (bula de Roflumilaste, Interações medicamentosas)

  • Fenobarbital + hiosciamina + atropina + escopolaminabarbitúricoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Fentermina + topiramatoestimulante do SNCGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Fluticasona + salmeterolcorticosteroideGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Formoterolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • FosfenitoínaanticonvulsivanteGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • GriseofulvinaantifúngicoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • IpratrópioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Ipratrópio + salbutamolanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Isoprenalina (isoproterenol)agonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Levossalbutamolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Lopinavir + ritonavirantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Lorlatinibeindutor da CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Mirabegronaagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Mitapivateindutor da CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Mitotanoindutor da CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Modafinilaestimulante do SNCGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Nafcilinaantibiótico da classe das penicilinasGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • NevirapinaantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • OxcarbazepinaanticonvulsivanteGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • PrimidonaanticonvulsivanteGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • RifabutinaantibióticoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • RifampicinaantibióticoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • RifapentinaantibióticoGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • RitonavirantirretroviralGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • Salbutamolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Salmeterolagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Suzetriginaindutor da CYP3A4Grave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • TeofilinametilxantinaGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Terbutalinaagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • TiotrópioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • TopiramatoanticonvulsivanteGrave

    • Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (bula de Roflumilaste, Advertências e precauções)

  • UmeclidínioanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Umeclidínio + vilanterolanticolinérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

  • Vibegronaagonista beta-adrenérgicoGrave

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (bula de Roflumilaste, Advertências e precauções)

Interações moderadas (54)

  • AmiodaronaantiarrítmicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • AtazanavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Cetoconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • CiclosporinaimunossupressorModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Cimetidinabloqueador H2Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Claritromicinaantibiótico macrolídeoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • DarunavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Darunavir + cobicistateantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Desogestrel + etinilestradiolanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Diacetato de etinodiol + etinilestradiolanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Diltiazembloqueador dos canais de cálcioModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • DronedaronaantiarrítmicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Drospirenona + etinilestradiolanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Elvitegravir + cobicistate + entricitabina + tenofovirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Eritromicinaantibiótico macrolídeoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • EstradiolestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Estradiol + dienogesteanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Estradiol + noretisteronaestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Estrogênios conjugadosestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Estrogênios conjugados + bazedoxifenoestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Estrogênios esterificados + metiltestosteronaestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Etonogestrel + etinilestradiolestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • EverolimoimunossupressorModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • FluvoxaminaISRSModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • FosamprenavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Fosaprepitantoinibidor da CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • FulvestrantoestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Imatinibeinibidor da CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • IsoniazidaantibióticoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Itraconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Ivacaftorinibidor da CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • LenacapavirantirretroviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • LevonorgestrelprogestinaModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Levonorgestrel + etinilestradiolanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • MedroxiprogesteronaprogestinaModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • MegestrolprogestinaModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Mifepristonainibidor da CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • NefazodonaantidepressivoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Nirmatrelvir + ritonavirantiviralModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Norelgestromina + etinilestradiolestrogênioModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • NoretisteronaprogestinaModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Noretisterona + etinilestradiolanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Norgestimato + etinilestradiolanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Norgestrel + etinilestradiolanticoncepcional oralModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Palbociclibeinibidor da CYP3A4Moderada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • PerampanelanticonvulsivanteModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • ProgesteronaprogestinaModerada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (bula de Roflumilaste, Interações medicamentosas)

  • Ranolazinamedicamento que prolonga o intervalo QTModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Suvorexantosedativo-hipnóticoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Ticagrelorantiagregante plaquetárioModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Verapamilbloqueador dos canais de cálcioModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (bula de Roflumilaste, Interações medicamentosas)

Menções leves (1)

  • RiociguatevasodilatadorLeve

    Clinical experience with co-administration of Adempas and other phosphodiesterase inhibitors (for example, milrinone, cilostazole, roflumilast) is limited. (bula de Riociguate, Interações medicamentosas)

Verifique Roflumilaste com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.